Brazil Halts Fiocruz–Takeda Dengue Production Plan as Vaccine Rollout Advances

Overview

• The Ministry of Health rejected the Fiocruz–Takeda PDP for Qdenga and reported no administrative appeal, and Fiocruz said it will not submit a new request.
• Fiocruz acknowledged limited space at its Bio‑Manguinhos complex, further constraining prospects for national production of Qdenga under the PDP model.
• The national immunization program plans to ship Qdenga doses for 10–14‑year‑olds to all 5,570 municipalities this month, with 9 million doses expected in 2026 and another 9 million in 2027 from Takeda.
• Anvisa has approved the single‑dose Butantan‑DV, and the Health Ministry purchased about 1.3 million doses for priority groups and targeted campaigns.
• Mass vaccination with Butantan‑DV is scheduled for Jan. 17–18 in Botucatu (SP), Nova Lima (MG) and Maranguape (CE) for residents 15–59, as Butantan begins enrolling 60–79‑year‑olds in trials to assess safety and immune response.